Clinical Trial Update: Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase II trial of pembrolizumab plus lenvatinib in advanced well-differentiated neuroendocrine tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Neuroendocrine Tumor

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Neuroendocrine Tumors, Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-03-26